Disparities in treatment delays among metastatic breast cancer patients: insights from nationwide electronic health records, 2011-2022.

IF 3 3区 医学 Q2 ONCOLOGY
Breast Cancer Research and Treatment Pub Date : 2025-04-01 Epub Date: 2025-01-07 DOI:10.1007/s10549-024-07593-3
Asal Pilehvari, Wen You, Gretchen Kimmick, Gloribel Bonilla, Roger Anderson
{"title":"Disparities in treatment delays among metastatic breast cancer patients: insights from nationwide electronic health records, 2011-2022.","authors":"Asal Pilehvari, Wen You, Gretchen Kimmick, Gloribel Bonilla, Roger Anderson","doi":"10.1007/s10549-024-07593-3","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>While previous research has highlighted treatment delay inequities in early-stage breast cancer and identified potential contributing factors, there is limited research on disparities in treatment delays for metastatic breast cancer (MBC). This study investigates these disparities in MBC treatment initiation, aiming to identify key factors crucial for improving timely access to care.</p><p><strong>Method: </strong>Nationwide Flatiron Health electronic health records-derived deidentified database, including females aged 18+ diagnosed with either De novo or relapsed MBC in the U.S. between 2011 and 2022. Treatment delay, defined as > 60 days between diagnosis and first-line treatment, was assessed as a binary variable. T-tests and chi-squared tests analyzed patient characteristics (age, race, insurance, diagnosis stage, metastasis site, phenotypes, etc.) among delayed and non-delayed groups. Logistic regression evaluated the association between clinical and non-clinical factors and treatment delays.</p><p><strong>Results: </strong>Among 20,617 patients with MBC, nearly 27% experienced treatment delays. These patients were generally younger, uninsured, historically marginalized, and newly diagnosed. Risk ratio analysis showed patients with only Medicare without secondary coverage (RR: 2.34, 95% CI [1.06, 5.16]) and uninsured (RR: 2.18, 95% CI [1.01, 4.76]) had higher risk of delays compared to those with commercial insurance. Historically marginalized patients had higher delay risk, ranging from 6% for Black patients to 12% for patients with not documented race/ethnicity background (p = 0.03) compared to White patients.\"</p><p><strong>Conclusion: </strong>Our study highlights significant disparities in MBC treatment delays. Patients from historically marginalized groups and those without health insurance coverage or with only Medicare coverage are highly likely to experience delays. Addressing these disparities is essential for equitable healthcare and improved outcomes.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"210 3","pages":"575-582"},"PeriodicalIF":3.0000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Cancer Research and Treatment","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10549-024-07593-3","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/7 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: While previous research has highlighted treatment delay inequities in early-stage breast cancer and identified potential contributing factors, there is limited research on disparities in treatment delays for metastatic breast cancer (MBC). This study investigates these disparities in MBC treatment initiation, aiming to identify key factors crucial for improving timely access to care.

Method: Nationwide Flatiron Health electronic health records-derived deidentified database, including females aged 18+ diagnosed with either De novo or relapsed MBC in the U.S. between 2011 and 2022. Treatment delay, defined as > 60 days between diagnosis and first-line treatment, was assessed as a binary variable. T-tests and chi-squared tests analyzed patient characteristics (age, race, insurance, diagnosis stage, metastasis site, phenotypes, etc.) among delayed and non-delayed groups. Logistic regression evaluated the association between clinical and non-clinical factors and treatment delays.

Results: Among 20,617 patients with MBC, nearly 27% experienced treatment delays. These patients were generally younger, uninsured, historically marginalized, and newly diagnosed. Risk ratio analysis showed patients with only Medicare without secondary coverage (RR: 2.34, 95% CI [1.06, 5.16]) and uninsured (RR: 2.18, 95% CI [1.01, 4.76]) had higher risk of delays compared to those with commercial insurance. Historically marginalized patients had higher delay risk, ranging from 6% for Black patients to 12% for patients with not documented race/ethnicity background (p = 0.03) compared to White patients."

Conclusion: Our study highlights significant disparities in MBC treatment delays. Patients from historically marginalized groups and those without health insurance coverage or with only Medicare coverage are highly likely to experience delays. Addressing these disparities is essential for equitable healthcare and improved outcomes.

转移性乳腺癌患者治疗延迟的差异:2011-2022年全国电子健康记录的见解
目的:虽然之前的研究已经强调了早期乳腺癌的治疗延迟不平等,并确定了潜在的影响因素,但对转移性乳腺癌(MBC)治疗延迟差异的研究有限。本研究调查了这些差异在MBC治疗开始,旨在确定关键因素,改善及时获得护理。方法:全国Flatiron Health电子健康记录来源的未识别数据库,包括2011年至2022年间在美国诊断为新生或复发的18岁以上女性MBC。治疗延迟,定义为从诊断到一线治疗之间60天,作为一个二元变量进行评估。t检验和卡方检验分析了延迟组和非延迟组的患者特征(年龄、种族、保险、诊断阶段、转移部位、表型等)。Logistic回归评估临床和非临床因素与治疗延误之间的关系。结果:在20,617例MBC患者中,近27%的患者出现了治疗延误。这些患者通常较年轻,没有保险,历史边缘化和新诊断。风险比分析显示,与有商业保险的患者相比,只有医疗保险而没有二级保险的患者(RR: 2.34, 95% CI[1.06, 5.16])和没有保险的患者(RR: 2.18, 95% CI[1.01, 4.76])有更高的延迟风险。与白人患者相比,历史上被边缘化的患者有更高的延迟风险,从黑人患者的6%到无种族/民族背景记录的患者的12% (p = 0.03)。“结论:我们的研究突出了MBC治疗延迟的显著差异。来自历史上被边缘化群体的患者,以及那些没有医疗保险或只有医疗保险覆盖的患者,极有可能经历延误。解决这些差异对于公平的医疗保健和改善结果至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.80
自引率
2.60%
发文量
342
审稿时长
1 months
期刊介绍: Breast Cancer Research and Treatment provides the surgeon, radiotherapist, medical oncologist, endocrinologist, epidemiologist, immunologist or cell biologist investigating problems in breast cancer a single forum for communication. The journal creates a "market place" for breast cancer topics which cuts across all the usual lines of disciplines, providing a site for presenting pertinent investigations, and for discussing critical questions relevant to the entire field. It seeks to develop a new focus and new perspectives for all those concerned with breast cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信